TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24126211
Drug: HAC1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAC1 vaccine (90 μg non-adjuvanted)
Study: 24126211
Drug: HAC1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAC1 vaccine (15 μg and 45 μg)
Study: 24126211
Drug: Approved monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approved monovalent H1N1 vaccine
Study: 22771827
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus sorafenib (gemcitabine 1000 mg/m² i.v., weekly seven times followed by 1 rest week, then weekly three times every 4 weeks plus sorafenib 200 mg, two tablets p.o., twice daily continuously)
Study: 22771827
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus placebo (gemcitabine 1000 mg/m² i.v., weekly seven times followed by 1 rest week, then weekly three times every 4 weeks plus placebo, two tablets p.o., twice daily continuously)
Study: 15361287
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg synthetic allitridum every day and 100 microg selenium every other day for one month each year from November 1989 to December 1991.
Study: 15361287
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules containing corn oid.
Study: 11550729
Drug: 5-session Preparing
Normalized name: Caviar Preparation
DrugBank: Caviar, unspecified (DB14241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-session Preparing for the Drug Free Years Program
Study: 9786103
Drug: Clomipramine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 150 mg/day plus Nortriptyline 50 mg/day
Study: 9786103
Drug: Clomipramine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 150 mg/day plus Placebo
Study: 3555942
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (propranolol)
Study: 21566299
Drug: Cinacalcet 30
Normalized name: cinacalcet 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet 30 mg daily with main meal, titrated monthly
Study: 21566299
Drug: Cinacalcet 90
Normalized name: cinacalcet 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet 90 mg once weekly and 120 mg midweek with main meal, titrated monthly
Study: 14732316
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (q8 hourly for 10 days)
Study: 14732316
Drug: Clarithromycin (q12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (q12 hourly for 10 days)
Study: 14732316
Drug: Cefprozil (q12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil (q12 hourly for 5 days)
Study: 11497016
Drug: Steroid and/or
Normalized name: Corticosteroid and/or corticosteroid derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid and/or anapolan treatment (BMT-)
Study: 7871339
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (doctors offered a WHO textbook on drug prescription and three monthly meetings with nurses and social workers)
Study: 2829371
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg twice a day for 1 day
Study: 2829371
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg twice a day for 2 days
Study: 2829371
Drug: Oral ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketoconazole and vaginal econazole nitrate (control)
Study: 24961447
Drug: Kochujang (34.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kochujang (34.5 g/d)
Study: 24198754
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg or 2 mg oromucosal nicotine spray
Study: 24022237
Drug: Placebo oromucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oromucosal nicotine spray
Study: 24198754
Drug: Nicotine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (1 mg or 2 mg)
Study: 21624391
Drug: Rivastigmine 0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 0, 3, or 6 mg daily for six consecutive days
Study: 14966574
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO) therapy at a pressure of 0.25 MPa
Study: 10881250
Drug: Galantamine 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 32 mg/d
Study: 10881250
Drug: Galantamine 24
Normalized name: galantamine 24 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 24 mg/d and 32 mg/d
Study: 9008256
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Fosinopril + 12.5 mg Hydrochlorothiazide
Study: 9008256
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Fosinopril + 12.5 mg Hydrochlorothiazide
Study: 12959315
Drug: Pazinaclone (DN‐2327)
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pazinaclone (DN‐2327) 4 mg
Study: 12959315
Drug: Pazinaclone (DN‐2327)
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pazinaclone (DN‐2327) 8 mg
Study: 3611334
Drug: Neurodevelopmental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental treatment (intensive physical therapy course for 6 weeks)
Study: 27395413
Drug: Hypoxic confinement
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxic confinement combined with daily moderate-intensity exercise (HAMB)
Study: 26248510
Drug: Low-dose rVSV-ZEBOV
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rVSV-ZEBOV (3×10^5 pfu)
Study: 26248510
Drug: High-dose rVSV-ZEBOV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rVSV-ZEBOV (1×10^7 pfu or 5×10^7 pfu)
Study: 12594139
Drug: Remifentanil (0.025,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.025, 0.05 and 0.1 micro g kg(‐1) min(‐1))
Study: 10955754
Drug: Ambulatory oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory oxygen at 2 l min(‐1)
Study: 8398588
Drug: R-verapamil 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-verapamil 500 mg
Study: 8398588
Drug: R-verapamil 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-verapamil 1000 mg
Study: 8398588
Drug: R-verapamil 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-verapamil 250 mg
Study: 8398588
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg racemic verapamil
Study: 3533370
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral nalmefene
Study: 26606735
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg twice daily for 24 months plus ASA ≤100 mg for one month
Study: 26606735
Drug: Conventional dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dual antiplatelet therapy (DAPT) with either ticagrelor or clopidogrel for 12 months plus ASA ≤100 mg for 24 months
Study: 24276953
Drug: Aprepitant (day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (day 1: 125 mg; days 2-3: 80 mg)
Study: 24276953
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (days 1-3: placebo)
Study: 22774396
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with myo-inositol (MI) and D-chiro-inositol (DCI)
Study: 15986825
Drug: Negative psychosocial
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative psychosocial factors (e.g., being a widower, divorced, low education, manual labor, pensioners, low social support)
Study: 12865375
Drug: Self‐administered behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered behavioral treatment using a self‐help booklet (control condition)
Study: 10369612
Drug: Fosinopril 10
Normalized name: fosinopril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 10 mg tablet
Study: 10369612
Drug: HCTZ 12.5
Normalized name: HCTZ 12.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 12.5 mg tablet
Study: 10369612
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet of fosinopril 10 mg plus HCTZ 12.5 mg
Study: 10369612
Drug: Coadministered tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministered tablets of fosinopril 10 mg and HCTZ 12.5 mg
Study: 10369612
Drug: Fosinopril 20
Normalized name: fosinopril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 20 mg tablet
Study: 10369612
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet of fosinopril 20 mg plus HCTZ 12.5 mg
Study: 10369612
Drug: Coadministered tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministered tablets of fosinopril 20 mg and HCTZ 12.5 mg
Study: 6148621
Drug: Cimetidine (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400-800 mg/day)
Study: 24549963
Drug: 200-mg imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg imatinib tablet
Study: 24549963
Drug: 2×100-mg imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2×100-mg imatinib tablets
Study: 22371023
Drug: fs-laser therapy
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: fs-laser therapy (simulated with modified contact lenses)
Study: 18391051
Drug: Standard cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive-behavioral treatment (CBT)
Study: 18391051
Drug: Brief cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive-behavioral treatment (CBT)
Study: 10069782
Drug: Oral methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine (L‐methionine 100 mg/kg)
Study: 10069782
Drug: Oral methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine preceded by vitamin C (1g/day, for 1 week)
Study: 2149673
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of etodolac
Study: 2149673
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg of etodolac
Study: 6130557
Drug: Destyrosine-gamma-endorphin (DTGE)
Normalized name: beta-endorphin human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Destyrosine-gamma-endorphin (DTGE) high doses (20-120 mg)
Study: 23313532
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus manual therapy
Study: 23313532
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus exercise therapy
Study: 23313532
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus combined exercise therapy and manual therapy
Study: 22108471
Drug: Viatromb (heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viatromb (heparin spraygel 2.400 IU/g)
Study: 19728560
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (CYP acetate 2 mg tablet with ethinylestradiol 0.25 mg)
Study: 19728560
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (CYP acetate 2 mg tablet with ethinylestradiol 0.25 mg)
Study: 11496446
Drug: Brief couple
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief couple therapy intervention (2 to 4 sessions)
Study: 8038871
Drug: Cognitive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive training combined with phosphatidylserine 2 x 200 mg/day
Study: 8038871
Drug: Cognitive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive training combined with pyritinol 2 x 600 mg/day
Study: 8038871
Drug: Cognitive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive training twice a week
Study: 1206472
Drug: high-justification-pill
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-justification-pill
Study: 1206472
Drug: no-justification-pill
Normalized name: No Doz Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: no-justification-pill
Study: 1206472
Drug: high-justification-no-pill
Normalized name: No Doz Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-justification-no-pill
Study: 1206472
Drug: no-pill-no-justification
Normalized name: No Doz Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: no-pill-no-justification
Study: 30673996
Drug: Spiritual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiritual therapy (12 sessions, 60 minutes each, twice a week)
Study: 26468453
Drug: Selenomethionine (SLM)
Normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selenomethionine (SLM) 3600 μg/m(2) twice daily for 7 days prior to CRT, once daily during CRT, and daily for 3 weeks following CRT
Study: 23554139
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups (PFMT and PFMT + TrA)
Study: 18646366
Drug: Clear gel
Normalized name: Tucks Clear Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear gel negative control toothpaste
Study: 17441971
Drug: Topiramate (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (mean modal dose ± SD = 100 ± 17 mg/day)
Study: 15479128
Drug: Leptin concentration
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin concentration in subcutaneous fat tissue
Study: 15479128
Drug: TNFalpha concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFalpha concentration in subcutaneous fat tissue
Study: 11398153
Drug: Ciprofibrate 100
Normalized name: ciprofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate 100 mg/d
Study: 11398153
Drug: Gemfibrozil 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 1,200 mg/d
Study: 7836516
Drug: Fertility drugs
Normalized name: Tests for fertility disturbances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fertility drugs
Study: 7836516
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no fertility drugs)
Study: 3400659
Drug: Estrogen treatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen treatment for 2 years
Study: 11966951
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 2 years
Study: 28643425
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine U100 (IGlar)
Study: 20511192
Drug: CED of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CED of cintredekin besudotox (CB) at 0.5 microg/mL administered over 96 hours via 2-4 intraparenchymal catheters after tumor resection
Study: 20511192
Drug: Gliadel wafers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliadel wafers (GW) at 3.85%/7.7 mg carmustine per wafer, maximum 8 wafers placed immediately after tumor resection
Study: 18455389
Drug: Protein ingestion
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein ingestion (15 g whey)
Study: 11837570
Drug: Antibacterial eradication
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial eradication therapy
Study: 10613232
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Ultrasound gel and Vaseline)
Study: 8573412
Drug: Alendronate 20
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 20 mg/day
Study: 8573412
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin 100 IU/day
Study: 1902992
Drug: Cefotaxime and
Normalized name: cefotaxime and beta-lactamase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime and Clindamycin (CC)
Study: 1902992
Drug: Both AGC
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both AGC and CC
Study: 6771815
Drug: 0.85 g
Normalized name: MENTHOL 0.85 g in 17 g TOPICAL PATCH [SINSINPAS COLD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.85 g alcohol/kg body weight
Study: 6771815
Drug: 0.63 g
Normalized name: phytosterol/om-3/dha/epa/fish 0.63 gram-232.5 mg-92.5 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.63 g alcohol/kg body weight
Study: 6771815
Drug: 0.41 g
Normalized name: PETROLATUM 0.41 g in 1 g TOPICAL OINTMENT [Equate Baby Advanced Healing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.41 g alcohol/kg body weight
Study: 28157725
Drug: Person-Centered Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Person-Centered Therapy (PCT)
Study: 23981368
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (10 sessions over 3 months)
Study: 23981368
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no placebo treatment)
Study: 17635487
Drug: Antimicrobial vaginal
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial vaginal pessary containing tetracycline and amphotericin B, administered twice a day for 14 days after LLETZ
Study: 16013901
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (fluoxetine [N = 42] and paroxetine [N = 43])
Study: 12542933
Drug: Patient medication
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient medication diaries
Study: 7648717
Drug: IgM-enriched IVIG
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM-enriched IVIG (250 mg/kg per day for 4 days)
Study: 7648717
Drug: Standard IVIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard IVIG (250 mg/kg per day for 4 days)
Study: 7648717
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no IVIG, supportive and antibiotic therapy)
Study: 2667612
Drug: Topical 1
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1 alpha,25-dihydroxyvitamin D3 (0.5 microgram applied twice daily)
Study: 345313
Drug: Oral pimozide
Normalized name: Pimozide
DrugBank: Pimozide (DB01100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pimozide
Study: 345313
Drug: Depot injections
Normalized name: methylprednisolone Injection [Depo-Medrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot injections of fluphenazine decanoate
Study: 31303099
Drug: Ultrafiltration therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrafiltration therapy
Study: 27546708
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin therapy
Study: 28003302
Drug: Conservative Treatment
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative Treatment
Study: 25216771
Drug: Umezu polyphenols
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umezu polyphenols (UP) 800 mg daily for 12 weeks
Study: 25216771
Drug: Placebo 0
Normalized name: Norethindrone;Placebo 0.35 MG; NA Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0 mg daily for 12 weeks
Study: 15266334
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (GEM) 1200 mg m(‐2) on days 1, 8 and 15 every 28 days
Study: 15266334
Drug: Paclitaxel (PTX)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (PTX) 100 mg m(‐2) on days 1, 8 and 15 every 28 days
Study: 15266334
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (GEM) 1000 mg m(‐2) plus Paclitaxel (PTX) 80 mg m(‐2) (GT) on days 1 and 8 every 21 days
Study: 15266334
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (GEM) 1000 mg m(‐2) plus Vinorelbine (VNR) 25 mg m(‐2) (GV) on days 1 and 8 every 21 days
Study: 11555525
Drug: Placebo CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo CPAP treatment
Study: 9928578
Drug: Dose-escalating CEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalating CEF
Study: 9928578
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of CEF followed by high-dose chemotherapy and autologous stem cell support
Study: 9928578
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy for 2 years
Study: 28077338
Drug: 10-day B-quadruple
Normalized name: amphotericin B 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day B-quadruple therapy (OM-triple + bismuth subcitrate 120 mg four times daily)
Study: 28077338
Drug: 10-day omeprazole-based
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day omeprazole-based triple therapy (OM-triple; omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily)
Study: 28077338
Drug: B-quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-quadruple therapy
Study: 25640470
Drug: Omalizumab (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (750 mg monthly)
Study: 23661521
Drug: Olanzapine (2.5‐15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5‐15 mg)
Study: 23661521
Drug: Sodium Valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Valproate (600‐1000 mg)
Study: 18285565
Drug: High-dose myoblasts
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose myoblasts
Study: 18285565
Drug: Myoblasts (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myoblasts (combined treatment)